SunTrust Initiates Coverage on Several Drug Manufacturers & Suppliers
More News related to ACL
- Alcon Posts 5.9 Percent Sales Growth for Third Quarter
- Trading Radar for 10/27: Visa (V), Baidu.com (BIDU), WYNN Resorts (WYNN), RF Micro (RFMD), BP (BP) Report
- Alcon (ACL) and Potentia Pharma Sign Licensing and Purchasing Agreement for Macular Degeneration Treatment
- Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
- Alcon Announces Third Quarter 2009 Financial Release and Conference Call Dates
More News related to AGN
- The Lowe Law Firm Files Suit over Alleged Botox Overdose
- Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
- Allergan (AGN) Posts Q3 EPS of $1.13, Topping Street; Guides FY09
- Don't Miss Out! The Registration Period for the 2010 IR Global Rankings Ends TOMORROW!
- Allergan Reports Third Quarter 2009 Operating Results
More News related to CEPH
- Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in Relapsed Indolent Non-Hodgkin's Lymphoma
- Cephalon, Inc. to Webcast R&D Day
- Mayo Clinic Proceedings Publishes Study of NUVIGIL in Patients with Shift Work Disorder
- Trading Review for Jazz Pharmaceuticals Inc. Issued by Beacon Equity
- Soleil Securities Reiterates a 'Buy' on Cephalon (CEPH)
More News related to New Coverage
- Wright Medical Group (WMGI) Announces FDA Approval For CONSERVE Plus Total Hip Resurfacing System
- Vascular Solutions (VASC) Receives 501(k) Clearance from U.S. FDA for GuideLiner Catheter
- Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
- Compugen (CGEN) Announces Discovery of Biomarker CGEN-40001 for Type 2 Diabetes
SunTrust initiates coverage on Alcon (NYSE: ACL), Allergan (NYSE: AGN), Ista Pharmaceuticals (Nasdaq: ISTA), Sepracor (Nasdaq: SEPR), & Shire (Nasdaq: SHPGY) with a Buy.\
SunTrust's price target on ACL is $155, AGN $58, ISTA $5, SEPR $24 & SHPGY is $53.
SunTrust initiates coverage on Cephalon (Nasdaq: CEPH) & Forest Labs (NYSE: FRX) with a Neutral rating.
Related Categories
New CoverageStocks Mentioned
+0.97
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
